Please assess the completion status of the following clinical trial:

Trial Title: Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* People who live in plain areas all year round and have not been to an altitude of 1500 meters or more in the past 30 days;~* Sign the informed consent form voluntarily.~Exclusion Criteria:~* Chronic physical or mental diseases, including hypertension, diabetes, coronary heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, migraine, anxiety, depression, insomnia, etc.;~* The female is pregnant or in the period of preparing for pregnancy or breast-feeding;~* Have a history of smoking;~* Have a history of thrombosis in the upper limbs;~* Severe damage to local soft tissues of upper limbs, fractures, etc.;~* Allergic to sulfa;~* Are taking one or more drugs;~* Past laboratory tests suggest hypokalemia, hyponatremia, or liver and kidney damage;~* Patients unsuitable for enrollment in the clinical trial according to investigators decision making.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Medicine Group (Type: ACTIVE_COMPARATOR): Start orally take Acetazolamide 2 days before entering the hypoxic room.
- RIPC Group (Type: ACTIVE_COMPARATOR): Start RIPC training twice daily, 6 days before entering the hypoxic room.
- Rapid RIPC Group (Type: EXPERIMENTAL): Start RIPC training forth daily, 3 days before entering the hypoxic room.
- Combined Group (Type: EXPERIMENTAL): Medicine + Rapid RIPC
- Control Group (Type: NO_INTERVENTION): Subjects do not receive specific interventions before entering the hypoxic room.

Based on this trial design, predict the completion outcome and termination type (if applicable).